By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Actavis 

Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


SEARCH JOBS

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video


Key Statistics


Email: actavis@actavis.com
Ownership: Public

Web Site: Actavis
Employees:
Symbol: ACT
 



Industry
Pharmaceutical






Company News
Actavis (ACT) Slashing More Than 400 Jobs in New York 3/18/2015 7:04:28 AM
Actavis (ACT) Announces Michael R. Gallagher And Peter J. Mcdonnell To Join Board Of Directors 3/17/2015 11:01:18 AM
Actavis (ACT) Completes Allergan (AGN) Acquisition 3/17/2015 9:45:13 AM
Actavis (ACT) Receives FDA Approval For VIIBRYD (vilazodone HCl) 20mg Once Daily As A Therapeutic Dose 3/17/2015 6:46:34 AM
European Commission (EC) Clears Actavis (ACT)' Pending Acquisition Of Allergan (AGN) 3/16/2015 9:25:20 AM
Actavis (ACT) Confirms Appeals Court Grants Injunction Pending Appeal Related To Generic Pulmicort RESPULES 3/13/2015 6:54:40 AM
Actavis (ACT) Receives FDA Approval Of SAPHRIS For Pediatric Patients (Age 10-17) For Acute Treatment Of Manic Or Mixed Episodes Of Bipolar I Disorder 3/13/2015 6:50:40 AM
Actavis (ACT) Announces Closing Of Public Offering Of Senior Notes In Connection With Pending Acquisition Of Allergan (AGN) 3/12/2015 12:52:44 PM
Actavis (ACT) And Allergan (AGN) Shareholders Approve Proposals Related To Actavis' Planned Acquisition Of Allergan 3/11/2015 7:40:53 AM
Actavis (ACT) Launches Generic Version Of Temovate (Clobetasol Cream 0.05%) 3/9/2015 2:20:34 PM
12345678910...
//-->